ERBB2 and breast carcinoma: Last but not least, relevant analyses from several large randomized clinical trials have been much updated recently, which makes it obliged to obtain the timely insight into a paradigm shift in how we deal with HER2-positive breast cancer patients in the adjuvant setting.